SCHEMBL6243293

SCHEMBL6243293

[O]CCc1cc2ccccc2o1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.66
AGXT P21549 1/20 0.55
HTR2B P41595 4/20 0.46
HTR1A P08908 1/20 0.46
FLT3 P36888 1/20 0.46
CYP2A6 P11509 1/20 0.46
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
CYP19A1 P11511 1/20 0.45
TYR P14679 1/20 0.44
DAO P14920 1/20 0.44
AKR1B1 P15121 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DRD2 P14416 3/20 0.43
CA2 P00918 1/20 0.43
ADRA2A P08913 1/20 0.43
DRD1 P21728 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969036 0.89 LOXL2 (0.61) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL2090461 0.88 LOXL2 (0.64) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL6013090 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1ACYP19A1
SCHEMBL4049122 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL4048647 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL297312 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL9037490 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL140395 0.80 LOXL2 (0.71) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL2249038 0.80 LOXL2 (0.60) LOXL2AGXTHTR2BHTR1AFLT3
SCHEMBL10368235 0.79 LOXL2 (0.55) LOXL2AGXTHTR2BHTR1AFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed
WO-2005025554-A2 DIPEPTIDYL PEPTIDASE IV INHIBITOR JAPAN TOBACCO INC. (JP) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 LOXL2 3866/4885AGXT 28/4885HTR2B 4755/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 LOXL2 3866/4885AGXT 28/4885HTR2B 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.